Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients

NCT06375473 · clinicaltrials.gov ↗

RECRUITING

Status

3000

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Irinotecan liposome II combination therapy regimen

Sponsor

Peking Union Medical College Hospital